{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:08:01Z","timestamp":1788984481253,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI 142523"],"award-info":[{"award-number":["AI 142523"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tafenoquine (TQ) was recently approved by the US Food and Drug Administration for prophylaxis of malaria and, in addition, for eradication of the hepatic phase of the relevant Plasmodium species. In this study, we evaluated the efficacy of TQ for treatment of Babesia microti infection in mice with severe combined immunodeficiency (SCID).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SCID mice were infected with 1.1\u20131.5 \u00d7 108\u00a0B. microti\u2013infected red blood cells by intraperitoneal injection. On day 3 or 4 postinfection, when parasitemia levels typically exceeded 10%, mice were treated with TQ vs vehicle alone, both administered by oral gavage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A single dose of TQ completely eliminated detectable parasites, with a &gt;90% reduction in the level of parasitemia within just 4 days. Before elimination, a conspicuous phenotypic change in the parasite was observed. Although parasitologic cure was not achieved, there was no evidence for the development of drug resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study suggests that TQ may be a highly useful drug to treat B. microti infection in patients. If further animal studies establish that a marked reduction in B. microti parasitemia can be reliably achieved with peak blood levels of TQ known to be well tolerated in humans, a clinical trial in patients should be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz119","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T07:12:02Z","timestamp":1555485122000},"page":"442-447","source":"Crossref","is-referenced-by-count":40,"title":["Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?"],"prefix":"10.1093","volume":"220","author":[{"given":"Dana G","family":"Mordue","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, New York Medical College, Valhalla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P","family":"Wormser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, New York Medical College, Valhalla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"2019070205530699000_CIT0001","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019070205530699000_CIT0002","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1001\/jama.2016.2884","article-title":"Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review","volume":"315","author":"Sanchez","year":"2016","journal-title":"JAMA"},{"key":"2019070205530699000_CIT0003","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3201\/eid1808.110988","article-title":"Vertical transmission of Babesia microti, United States","volume":"18","author":"Joseph","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"2019070205530699000_CIT0004","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5858\/arpa.2017-0250-RS","article-title":"Transfusion-transmitted babesiosis","volume":"143","author":"Villatoro","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"2019070205530699000_CIT0005","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1056\/NEJM200011163432004","article-title":"Atovaquone and azithromycin for the treatment of babesiosis","volume":"343","author":"Krause","year":"2000","journal-title":"N Engl J Med"},{"key":"2019070205530699000_CIT0006","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20151519","article-title":"Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone","volume":"213","author":"Lawres","year":"2016","journal-title":"J Exp Med"},{"key":"2019070205530699000_CIT0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2016.02.016","article-title":"Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis","volume":"85","author":"Raffalli","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019070205530699000_CIT0008","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019070205530699000_CIT0009","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2307\/3277582","article-title":"The \u201cGray\u201d strain of Babesia microti from a human case established in laboratory animals","volume":"56","author":"Gleason","year":"1970","journal-title":"J Parasitol"},{"key":"2019070205530699000_CIT0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1475-2875-13-141","article-title":"Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections","volume":"13","author":"Li","year":"2014","journal-title":"Malar J"},{"key":"2019070205530699000_CIT0011","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00343-15","article-title":"Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics","volume":"59","author":"Vuong","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019070205530699000_CIT0012","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/IJN.S76317","article-title":"Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice","volume":"10","author":"Melariri","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"2019070205530699000_CIT0013","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12936-016-1632-8","article-title":"Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei","volume":"15","author":"Milner","year":"2016","journal-title":"Malar J"},{"key":"2019070205530699000_CIT0014","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1086\/379718","article-title":"Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis","volume":"37","author":"Edstein","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019070205530699000_CIT0015","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy939","article-title":"Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled phase 1b study [manuscript published online ahead of print 1 November 2018]","author":"McCarthy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019070205530699000_CIT0016","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","article-title":"First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial","volume":"58","author":"Brueckner","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"2019070205530699000_CIT0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/AAC.41.1.91","article-title":"Evaluation of selected antiprotozoal drugs in the Babesia microti\u2013hamster model","volume":"41","author":"Marley","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2019070205530699000_CIT0018","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jtm\/tay110","article-title":"Tafenoquine for travelers\u2019 malaria: evidence, rationale and recommendations","volume":"1","author":"Baird","year":"2018","journal-title":"J Travel Med"},{"key":"2019070205530699000_CIT0019","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: first global approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"2019070205530699000_CIT0020","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/DDDT.S61443","article-title":"Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date","volume":"10","author":"Ebstie","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2019070205530699000_CIT0021","first-page":"5356","article-title":"Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis","volume":"54","author":"Carvalho","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019070205530699000_CIT0022","first-page":"376","article-title":"Comparison of a quantitative PCR assay with peripheral blood smear examination for detection and quantitation of Babesia microti infection in humans","volume":"6","author":"Wang","year":"2015","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz119\/28665760\/jiz119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/3\/442\/28896048\/jiz119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T23:39:00Z","timestamp":1569022740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/220\/3\/442\/5490825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,5,17]]},"published-print":{"date-parts":[[2019,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz119","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,5,17]]}}}